Equities

Gentian Diagnostics ASA

Gentian Diagnostics ASA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)41.00
  • Today's Change-2.60 / -5.96%
  • Shares traded25.00
  • 1 Year change+3.02%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of NOK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments8882115
Total Receivables, Net171923
Total Inventory373930
Prepaid expenses------
Other current assets, total--0.00--
Total current assets142139167
Property, plant & equipment, net182219
Goodwill, net------
Intangibles, net212725
Long term investments0.10----
Note receivable - long term------
Other long term assets--0.000.00
Total assets181188212
LIABILITIES
Accounts payable3.714.444.98
Accrued expenses------
Notes payable/short-term debt000
Current portion long-term debt/capital leases4.043.704.11
Other current liabilities, total181413
Total current liabilities252223
Total long term debt9.011214
Total debt131519
Deferred income tax0.07----
Minority interest------
Other liabilities, total0----
Total liabilities343437
SHAREHOLDERS EQUITY
Common stock1.541.541.54
Additional paid-in capital294294294
Retained earnings (accumulated deficit)(167)(156)(133)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total181512
Total equity147154175
Total liabilities & shareholders' equity181188212
Total common shares outstanding151515
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.